Bayesian designs and the control of frequentist characteristics: A practical solution

Biometrics

Volumn 71, Issue 1, 2015, Pages 218-226

  Ventz, Steffen ^a   Trippa, Lorenzo ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bayesian design; Clinical trials; Decision theory; Frequentist constraints

Indexed keywords

OPTIMAL SYSTEMS;

BAYESIAN DESIGN; CLINICAL TRIAL; FALSE DISCOVERY RATE; FREQUENTIST; FREQUENTIST CONSTRAINT; OPERATING CHARACTERISTICS; OPTIMAL DESIGN; PRACTICAL SOLUTIONS; TYPE-I ERROR; UTILITY FUNCTIONS;

DECISION THEORY;

BAYESIAN ANALYSIS; DECISION MAKING; ERROR ANALYSIS; LITERATURE REVIEW; MEDICAL GEOGRAPHY; PARAMETERIZATION; SIMULATION; STATISTICAL ANALYSIS;

ALGORITHM; BAYES THEOREM; BIOMETRY; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; EPIDEMIOLOGY; MATHEMATICAL COMPUTING; METHODOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ALGORITHMS; BAYES THEOREM; BIOMETRY; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; EPIDEMIOLOGIC METHODS; MODELS, STATISTICAL; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 84926142505     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/biom.12226     Document Type: Article

References (36)

1. Anscombe, F. (1963). Sequential medical trials. Journal of the American Statistical Association 58, 384-387.
2. Armitage, P., McPherson, C. K., and Rowe, B. C. (1969). Repeated significance tests on accumulating data. Journal of the Royal Statistical Society, Series A 132, 234-244.
3. Berry, D. A. and Ho, C.-H. (1988). One-sided sequential stopping boundaries for clinical trials: A decision-theoretic approach. Biometrics 44, 219-227.
4. Berry, S. M., Carlin, B. P., Lee, J. J., and Müller, P. (2010). Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: CRC Press.
5. Berry, S. M. and Kadane, J. B. (1997). Optimal Bayesian randomization. Journal of the Royal Statistical Society, Series B 59, 813-819.
6. Betensky, R. A. (1997). Early stopping to accept H0 based on conditional power: Approximations and comparisons. Biometrics 53, 794-806.
7. Carlin, B. P., Kadane, J. B., and Gelfand, A. E. (1998). Approaches for optimal sequential decision analysis in clinical trials. Biometrics 54, 964-975.
8. Casella, G. and Berger, R. L. (1987). Reconciling Bayesian and frequentist evidence in one-sided testing problems. Journal of the American Statistical Association 82, 106-111.
9. Chen, M.-H. and Ibrahim, J. G. (2006). The relationship between the power prior and hierarchical models. Bayesian Analysis 1, 551-574.
10. Chevret, S. (2012). Bayesian adaptive clinical trials: A dream for statisticians only? Statistics in Medicine 31, 20-30.
11. Chow, S.-C., Chiang, C., Liu, J.-P., and Hsiao, C.-F. (2012). Statistical methods for bridging studies. Journal of Biopharmaceutical Statistics 22, 903-915.
12. Christen, J. A., Müller, P., Wathen, K., and Wolf, J. (2004). A Bayesian randomized clinical trial: A decision-theoretic sequential design. The Canadian Journal of Statistics 32, 387-402.
13. Coleman, R. L. (2007). Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. Current Oncology Reports 9, 469-471.
14. Cornfield, J. (1966). Sequential trials, sequential analysis and the likelihood principle. American Statistician 20, 18-23.
15. DeGroot, M. H. (1973). Doing what comes naturally: Interpreting a tail area as a posterior probability or a likelihood ratio. Journal of the American Statistical Association 68, 966-969.
16. Ding, M., Rosner, G. L., and Müller, P. (2008). Bayesian optimal design for phase II screening trials. Biometrics 64, 886-894.
17. Efron, B. (1986). Why isn't everybody Bayesian? The American Statistician 40, 1-5.
18. Freidlin, B., Korn, E. L., Gray, R., and Martin, A. (2008). Multi-arm clinical trials of new agents: Some design considerations. Clinical Cancer Research 14, 4368-4371.
19. International Conference on Harmonisation (1998). Tripartite guidance E5, ethnic factors in the acceptability of foreign data. Federal Register 83, 31790-31796.
20. Ioannidis, J. P. (2013). Mega-trials for blockbusters. Journal of the American Medical Association 309, 239-240.
21. Lewis, R. J. and Berry, D. A. (1994). Group sequential clinical trials: A classical evaluation of Bayesian decision-theoretic designs. Journal of the American Statistical Association 89, 1528-1534.
22. Lewis, R. J., Lipsky, A. M., and Berry, D. A. (2007). Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: A frequentist evaluation. Clinical Trials 4, 5-14.
23. Lindley, D. V. (1994). Discussion of "Bayesian approaches to randomized trials" by D.J. Spiegelhalter, L.S. Freedman, and M.K.B. Parmar, Journal of the Royal Statistical Society, Series A 157, 393.
24. McPherson, C. K. and Armitage, P. (1971). Repeated significance tests on accumulating data when the null hypothesis is not true. Journal of the Royal Statistical Society, Series A 134, 15-25.
25. Müller, P., Berry, D., Grieve, A., Smith, M., and Krams, M. (2006). Simulation-based sequential Bayesian design. Journal of Statistical Planning and Inference 137, 3140-3150.
26. O'Brien, P. C. and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics 35, 549-556.
27. Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika 64, 191-199.
28. Pratt, J. W. (1965). Bayesian interpretation of standard inference statements. Journal of the Royal Statistical Society, Series B 27, 169-203.
29. Proschan, M. A., Lan, K. G., and Wittes, J. T. (2006). Statistical Monitoring of Clinical Trials A Unified Approach. New York: Springer.
30. R Core Team (2013). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
31. Rossell, D., Müller, P., and Rosner, G. L. (2007). Screening designs for drug development. Biostatistics 8, 595-608.
32. Sandler, A., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M., Gregor, A., Nguyen, B., Niyikiza, C., and Einhorn, L. (2000). Phase III trial of Gemcitabine plus Cisplatin versus Cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology 18, 122-130.
33. Santis, M. D., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., Collette, S., Lorent, J., de Wit, R., and Sylvester, R. (2012). Randomized phase II/III trial assessing Gemcitabine/Carboplatin and Methotrexate/ Carboplatin/Vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. Journal of Clinical Oncology 30, 191-199.
34. Spiegelhalter, D., Abrams, K., and Myles, J. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: Wiley.
35. Stallard, N., Thall, P. F., and Whitehead, J. (1999). Decision theoretic designs for phase II clinical trials with multiple outcomes. Biometrics 55, 971-977.
36. Trippa, L., Rosner, G. L., and Müller, P. (2012). Bayesian enrichment strategies for randomized discontinuation trials. Biometrics 68, 203-211.